247 related articles for article (PubMed ID: 30051601)
1. Chemistry-driven Hit-to-lead Optimization Guided by Structure-based Approaches.
Hoffer L; Muller C; Roche P; Morelli X
Mol Inform; 2018 Sep; 37(9-10):e1800059. PubMed ID: 30051601
[TBL] [Abstract][Full Text] [Related]
2. Computational Methods Used in Hit-to-Lead and Lead Optimization Stages of Structure-Based Drug Discovery.
Heifetz A; Southey M; Morao I; Townsend-Nicholson A; Bodkin MJ
Methods Mol Biol; 2018; 1705():375-394. PubMed ID: 29188574
[TBL] [Abstract][Full Text] [Related]
3. Docking and Virtual Screening in Drug Discovery.
Kontoyianni M
Methods Mol Biol; 2017; 1647():255-266. PubMed ID: 28809009
[TBL] [Abstract][Full Text] [Related]
4. Fragment based drug design: from experimental to computational approaches.
Kumar A; Voet A; Zhang KY
Curr Med Chem; 2012; 19(30):5128-47. PubMed ID: 22934764
[TBL] [Abstract][Full Text] [Related]
5. Fragment-based drug discovery and molecular docking in drug design.
Wang T; Wu MB; Chen ZJ; Chen H; Lin JP; Yang LR
Curr Pharm Biotechnol; 2015; 16(1):11-25. PubMed ID: 25420726
[TBL] [Abstract][Full Text] [Related]
6. [Fragment-based drug discovery: concept and aim].
Tanaka D
Yakugaku Zasshi; 2010 Mar; 130(3):315-23. PubMed ID: 20190516
[TBL] [Abstract][Full Text] [Related]
7. [Computational chemistry in structure-based drug design].
Cao R; Li W; Sun HZ; Zhou Y; Huang N
Yao Xue Xue Bao; 2013 Jul; 48(7):1041-52. PubMed ID: 24133970
[TBL] [Abstract][Full Text] [Related]
8. In-silico guided discovery of novel CCR9 antagonists.
Zhang X; Cross JB; Romero J; Heifetz A; Humphries E; Hall K; Wu Y; Stucka S; Zhang J; Chandonnet H; Lippa B; Ryan MD; Baber JC
J Comput Aided Mol Des; 2018 Apr; 32(4):573-582. PubMed ID: 29582229
[TBL] [Abstract][Full Text] [Related]
9. Discovery and Development of ATP-Competitive mTOR Inhibitors Using Computational Approaches.
Luo Y; Wang L
Curr Pharm Des; 2017 Nov; 23(29):4321-4331. PubMed ID: 28699534
[TBL] [Abstract][Full Text] [Related]
10. Recent advances in structure-based drug design and virtual screening of VEGFR tyrosine kinase inhibitors.
Hoi PM; Li S; Vong CT; Tseng HH; Kwan YW; Lee SM
Methods; 2015 Jan; 71():85-91. PubMed ID: 25239735
[TBL] [Abstract][Full Text] [Related]
11. Fragment-based drug design: computational & experimental state of the art.
Hoffer L; Renaud JP; Horvath D
Comb Chem High Throughput Screen; 2011 Jul; 14(6):500-20. PubMed ID: 21521152
[TBL] [Abstract][Full Text] [Related]
12. Rapid Identification of Potential Drug Candidates from Multi-Million Compounds' Repositories. Combination of 2D Similarity Search with 3D Ligand/Structure Based Methods and In Vitro Screening.
Szilágyi K; Flachner B; Hajdú I; Szaszkó M; Dobi K; Lőrincz Z; Cseh S; Dormán G
Molecules; 2021 Sep; 26(18):. PubMed ID: 34577064
[TBL] [Abstract][Full Text] [Related]
13. Fragment-Based Discovery and Optimization of Enzyme Inhibitors by Docking of Commercial Chemical Space.
Rudling A; Gustafsson R; Almlöf I; Homan E; Scobie M; Warpman Berglund U; Helleday T; Stenmark P; Carlsson J
J Med Chem; 2017 Oct; 60(19):8160-8169. PubMed ID: 28929756
[TBL] [Abstract][Full Text] [Related]
14. Computational drug discovery.
Ou-Yang SS; Lu JY; Kong XQ; Liang ZJ; Luo C; Jiang H
Acta Pharmacol Sin; 2012 Sep; 33(9):1131-40. PubMed ID: 22922346
[TBL] [Abstract][Full Text] [Related]
15. From Protein Structure to Small-Molecules: Recent Advances and Applications to Fragment-Based Drug Discovery.
Ferreira LG; Andricopulo AD
Curr Top Med Chem; 2017; 17(20):2260-2270. PubMed ID: 28240184
[TBL] [Abstract][Full Text] [Related]
16. Contributions of computational chemistry and biophysical techniques to fragment-based drug discovery.
Gozalbes R; Carbajo RJ; Pineda-Lucena A
Curr Med Chem; 2010; 17(17):1769-94. PubMed ID: 20345344
[TBL] [Abstract][Full Text] [Related]
17. Harmonization of QSAR Best Practices and Molecular Docking Provides an Efficient Virtual Screening Tool for Discovering New G-Quadruplex Ligands.
Castillo-González D; Mergny JL; De Rache A; Pérez-Machado G; Cabrera-Pérez MA; Nicolotti O; Introcaso A; Mangiatordi GF; Guédin A; Bourdoncle A; Garrigues T; Pallardó F; Cordeiro MN; Paz-Y-Miño C; Tejera E; Borges F; Cruz-Monteagudo M
J Chem Inf Model; 2015 Oct; 55(10):2094-110. PubMed ID: 26355653
[TBL] [Abstract][Full Text] [Related]
18. Overview on the current status of virtual high-throughput screening and combinatorial chemistry approaches in multi-target anticancer drug discovery; Part I.
Geromichalos GD; Alifieris CE; Geromichalou EG; Trafalis DT
J BUON; 2016; 21(4):764-779. PubMed ID: 27685895
[TBL] [Abstract][Full Text] [Related]
19. Modern drug discovery technologies: opportunities and challenges in lead discovery.
Guido RV; Oliva G; Andricopulo AD
Comb Chem High Throughput Screen; 2011 Dec; 14(10):830-9. PubMed ID: 21843147
[TBL] [Abstract][Full Text] [Related]
20. Computational approaches for drug discovery.
Hung CL; Chen CC
Drug Dev Res; 2014 Sep; 75(6):412-8. PubMed ID: 25195585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
